Obesity Care Needs More Cardiology Support, Suggest 2 New Studies
ACC.2024: Two abstracts presented during the ACC Scientific Sessions indicate cardiologists are very hesitant to prescribe medical therapy for obesity.
Sustained LDL-C Control in High-Risk Group via Remote Lipid Program: Daily Dose
Your daily dose of the clinical news you may have missed.
CAC Progression in Postmenopausal Women Found Double that of Men in New Research
ACC.24: Loss of estrogen's cardioprotective effect could account for the 2-fold greater increase in CAC score seen among postmenopausal women compared with men.
Vaccination of Older Adults Against RSV Could Reduce Symptomatic Cases by 1 Million per Year: Modeling Study
The study looked at the impact over 3 years but found that most of the averted burden, including more than 8000 fewer deaths, occur in the first year after vaccination.
Young Adults Prescribed ADHD Stimulants May Face Higher Risk of Cardiomyopathy
ACC.24: Data showed that participants with ADHD who were prescribed stimulants were 17% more likely to develop cardiomyopathy at 1 year.
Erenumab Rx Early in Episodic Migraine Found Superior to Oral Prophylactic Agents for Efficacy, Tolerability, Adherence
The phase 4 APPRAISE trial found greater efficacy with erenumab after failure with 1 or 2 other preventives vs ongoing treatment with the nonspecific oral agents.
Disparities in Coronary Artery Calcium Screening: Daily Dose
Icosapent Ethyl Reduces MACE Across Range of Baseline Lp(a): REDUCE-IT Analysis
ACC.24: Icosapent ethyl was associated with reduced rate of MACE at all baseline levels of Lp(a) in participants with elevated TG and at high risk for CVD.
FDA Approves Aprocitentan for Treatment-Resistant HTN: Daily Dose
FDA Issues Warning Letters to 6 Companies Marketing Misbranded OTC Topical Analgesics
Specifically, the topical analgesics, available over the counter, may contain higher than labeled concentrations of lidocaine, according to the agency.
FDA Approves Vadadustat for Treatment of Anemia due to CKD in Patients on Dialysis
The FDA approved the oral medication to treat anemia in adult patients with chronic kidney disease on dialysis for at least 3 months.
Blood-Based DNA Test for Colorectal Cancer: Daily Dose
Remission from Type 2 Diabetes via Lifestyle Intervention Reduces Risk for CVD, CKD
Longer duration of remission was associated with a greater reduction in CKD and CVD risk, according to a post hoc analysis of the Look AHEAD study.
COVID-19 Vaccines Reduce Risk of Cardiac, Thromboembolic Outcomes: Daily Dose
Moderna Next-Gen mRNA COVID-19 Vaccine Meets Primary Endpoints in NextCOVE Phase 3 Trial
The mRNA bivalent vaccine candidate produced a "more robust" immune response vs Spikevax and particularly in adults over the age of 65 years, said Moderna.
Viking Therapeutics Oral Antiobesity Agent Returns Positive Results in Small Study
The once daily tablet, VK2375, is headed to a phase 2 trial later this year and is an oral version of Viking's investigational injectable GLP-1/GIP mimetic currently in phase 2.
Bempedoic Acid Associated with Reduced CV Risk in Statin-Intolerant Individuals Regardless of Ethnicity
ACC.24: Data from an analysis of the CLEAR Outcomes trial showed bempedoic acid was well-tolerated and reduced CV events in Hispanic/Latinx and non-Hispanic/Latinx participants.
Steven Nissen, MD, Discusses Historic Bempedoic Acid Labeling for CV Risk Reduction
CLEAR Outcomes PI Steven Nissen, MD, links findings from the pivotal trial with labeling updates that make bempedoic acid the only nonstatin agent approved to reduce CV risk.
Sotagliflozin Impact on Stroke, MI to Be Explored in 4 Posters at ACC.24
The novel SGLT-2/SGLT-1 inhibitor reduced risk of stroke, MI, and demonstrates significant antiplatelet activity in post-hoc analyses of SCORED phase 3 trial.
New Data Shed Light on Disparities in Coronary Artery Calcium Screening
ACC.24: Findings showed a disproportionate distribution of CAC screening that favors White, educated, affluent, English-speaking individuals.
